Clinical Scorecard: Genetic Mutation Analysis and Clinical Phenotypes in 45 Patients with Neonatal-Onset Methylmalonic Acidemia
At a Glance
Category
Detail
Condition
Key Mechanisms
Deficiency in methylmalonyl-CoA mutase or defects in cobalamin metabolism (e.g., defects in the transport or conversion of vitamin B12) leading to toxic metabolite accumulation.
Target Population
Care Setting
Key Highlights
Common manifestations include feeding difficulties (60.0%), failure to thrive (57.8%), jaundice (46.7%), respiratory distress (40.0%), and impaired consciousness (28.9%).
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Follow-up visits scheduled 1–2 months post-discharge, then every 3–6 months, with specific parameters for monitoring metabolic status and growth.
Risks
Patient & Prescribing Data
Neonates diagnosed with MMA.
Treatment includes vitamin B12, L-carnitine, and dietary management for isolated MMA.
Clinical Best Practices
Early diagnosis and prompt intervention are essential for improving prognosis. Utilize genetic testing for confirmation of MMA subtype and consider it for all suspected cases.
